# Poolbeg Pharma promising results for POLB 001 in cancer immunotherapy-induced CRS

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-promising-results-for-polb-001-in-cancer-immunotherapy-induced-crs/4121138607
- Published: 2024-01-17T07:08:17+00:00
- Author: Amilia Stone

**[Poolbeg Pharma plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)**(
[LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF’), a biopharmaceutical company focussed on the development and commercialisation
of innovative medicines targeting diseases with a high unmet medical need, has announced
promising _in vivo_ results for POLB 001 in addressing cancer immunotherapy-induced
CRS.

**Key highlights**

–      Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an 
_in vivo_ model

–      Data strengthens and facilitates the expansion of patent applications for
POLB 001 in cancer immunotherapy-induced CRS

–      Independent Advisory Board supportive of POLB 001’s potential to both prevent
and treat cancer immunotherapy-induced CRS

**Positive study results**

POLB 001 demonstrated efficacy in reducing cancer immunotherapy-induced CRS in an
_in vivo_ animal model with CRS symptoms significantly improved following administration
of POLB 001. Reductions were seen in all serum proinflammatory cytokines tested.

The results, together with the data from the recent LPS human challenge trial, further
support the Company’s strategic expansion of the Phase II ready POLB 001 to treat
and prevent cancer immunotherapy-induced CRS. The data also strengthens and facilitates
the expansion of patent applications for POLB 001 in cancer immunotherapy-induced
CRS.

**Market opportunity estimated at over US$1 billion**

Largely due to the CRS risk (which can be life threatening), administration of cancer
immunotherapies, such as bispecific antibodies, is currently restricted to specialist
cancer centres which limits uptake of these effective therapies. As an oral therapy
to prevent or treat CRS, POLB 001 has the potential to enable broader use of cancer
immunotherapies in an outpatient setting. The Company believes that POLB 001 represents
a significant market opportunity estimated at > US$1 billion in Multiple Myeloma,
High Grade Lymphoma and Acute Lymphoblastic Leukaemia alone. Cancer immunotherapies
are being widely developed across a broader range of haematological malignancies,
solid tumours and immune inflammatory diseases, which represents an even greater
market opportunity.

In the U.S., the American Cancer Society estimates that there will be 24.6 million
cases of cancer by 2030^(1,2). Cancer immunotherapies, such as bispecific antibodies
and CAR T cell therapy, are rapidly moving into earlier lines of treatment in many
tumour types, with these markets anticipated to grow to US$100bn+ (_~35% CAGR)_ 
by 2030^(3).

**Independent Advisory Board Supportive of POLB 001’s Potential **

Poolbeg Pharma convened an Independent Advisory Board with international Key Opinion
Leaders, healthcare payers and clinical trial experts, which endorsed the attractiveness
of POLB 001’s Target Product Profile (TPP) and its potential as an oral therapy 
to address the significant unmet medical need of cancer immunotherapy-induced CRS.
POLB 001 has been shown to reduce hyperinflammation without complete ablation of
an effective immune response, which makes it potentially a very attractive therapy
for this disease area.

> **Prof. Gareth Morgan, NYU Langone, United States** **said** _“Bispecific antibodies
> will only be delivered in specialist cancer centres until there is a way to make
> them safer. POLB 001 could make treatment safe enough to extend bispecifics to
> a much wider patient population”._

> **Dr Martin Kaiser, Reader/Associate Professor in Molecular Haematology at The
> Institute of Cancer Research and Haematology Consultant at The Royal Marsden Hospital
> said,** _“Patients undergoing cancer immunotherapy treatment that suffer with 
> CRS can be critically ill which, alongside a weakened immune system, can further
> increase their risk of infection. Preventing CRS in the first instance would have
> a significant impact on patient health and wellbeing, as well as reducing the 
> burden on the healthcare system. Current CRS treatments require intravenous infusion,
> which is difficult to deliver out of hospital, and some can only be used off label
> in combination with bispecific antibodies. If there was a therapy that was orally
> delivered, a whole lot of infrastructure requirement falls away.”_

> **David Allmond, Chief Business Officer of Poolbeg Pharma, commented:** _“POLB
> 001 has the potential to revolutionise the impact of cancer immunotherapies by
> enabling safer and broader use in an outpatient setting, reducing healthcare resource
> utilisation and making these next generation cancer treatments more widely available
> to the patients that need them. The pharmaceutical sector is seeking an effective
> solution for CRS and, as an oral therapy, we believe there is a significant opportunity
> for POLB 001 to meet this critical unmet medical need and have a positive impact
> on global health.”_

**References**

1.     The American Cancer Society (ACS)  

2.     The International Agency for Research on Cancer (IARC)

3.     CAR T Cell Therapy Market Analysis 2023-2030; Bispecific Antibodies Market
Size, Share & Trends Analysis Report, Grand View Research

Share on: